Advisors Asset Management, Inc. Sage Therapeutics, Inc. Transaction History

Advisors Asset Management, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$58.41 - $89.06 $13,551 - $20,661	-232 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$41.13 - $62.45 $1,151 - $1,748	-28 Reduced 10.77%	232 $14,000
Q2 2020 Aug 12, 2020	SELL	$25.95 - $43.15 $181 - $302	-7 Reduced 2.62%	260 $11,000
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $156 - $463	-6 Reduced 2.2%	267 $8,000
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $60 - $154	1 Added 0.37%	273 $20,000
Q3 2019 Nov 14, 2019	SELL	$140.29 - $189.96 $264,727 - $358,454	-1,887 Reduced 87.4%	272 $38,000
Q2 2019 Aug 14, 2019	BUY	$157.85 - $183.09 $259,347 - $300,816	1,643 Added 318.41%	2,159 $395,000
Q1 2019 May 15, 2019	SELL	$89.33 - $163.65 $893 - $1,636	-10 Reduced 1.9%	516 $82,000
Q4 2018 Jan 31, 2019	SELL	$81.94 - $139.71 $3,113 - $5,308	-38 Reduced 6.74%	526 $50,000
Q3 2018 Nov 15, 2018	BUY	$138.11 - $169.04 $3,867 - $4,733	28 Added 5.22%	564 $80,000
Q2 2018 Aug 22, 2018	SELL	$140.36 - $175.76 $21.4 Million - $26.8 Million	-152,718 Reduced 99.65%	536 $84,000
Q2 2018 Aug 15, 2018	BUY	$140.36 - $175.76 $21.5 Million - $26.9 Million	153,254 New	153,254 $84,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $340M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.